195 related articles for article (PubMed ID: 2620186)
1. Striatal dopamine receptor supersensitivity after long-term haloperidol treatment of hypophysectomized rats.
DeLucia R; Scavone C; Camillo MA
Braz J Med Biol Res; 1989; 22(6):741-3. PubMed ID: 2620186
[TBL] [Abstract][Full Text] [Related]
2. Hypophysectomy may non-selectively alter pharmacokinetic parameters to enhance the ability of haloperidol to increase striatal dopamine receptor density in the rat.
Simpson MD; Jenner P; Marsden CD
Biochem Pharmacol; 1986 Oct; 35(20):3501-6. PubMed ID: 3768037
[TBL] [Abstract][Full Text] [Related]
3. Hypophysectomy prevents the striatal dopamine receptor supersensitivity produced by chronic haloperidol treatment.
Hruska RE; Ludmer LM; Silbergeld EK
Eur J Pharmacol; 1980 Aug; 65(4):455-6. PubMed ID: 7408951
[No Abstract] [Full Text] [Related]
4. Hypophysectomy does not prevent development of striatal dopamine receptor supersensitivity induced by repeated neuroleptic treatment.
Jenner P; Rupniak NM; Hall MD; Dyer R; Leigh N; Marsden CD
Eur J Pharmacol; 1981 Nov; 76(1):31-6. PubMed ID: 6119220
[TBL] [Abstract][Full Text] [Related]
5. Relationship between dopamine receptor occupation by spiperone and acetylcholine levels in the rat striatum after long-term haloperidol treatment depends on dopamine innervation.
Korf J; Sebens JB
J Neurochem; 1987 Feb; 48(2):516-21. PubMed ID: 2878979
[TBL] [Abstract][Full Text] [Related]
6. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
Schweitzer JW; Schwartz R; Friedhoff AJ
Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
[TBL] [Abstract][Full Text] [Related]
7. Differential alterations in striatal dopamine receptor sensitivity induced by repeated administration of clinically equivalent doses of haloperidol, sulpiride or clozapine in rats.
Rupniak NM; Kilpatrick G; Hall MD; Jenner P; Marsden CD
Psychopharmacology (Berl); 1984; 84(4):512-9. PubMed ID: 6441952
[TBL] [Abstract][Full Text] [Related]
8. Differences in the time course of haloperidol-induced up-regulation of rat striatal and mesolimbic dopamine receptors.
Prosser ES; Csernansky JG; Hollister LE
Life Sci; 1988; 43(8):715-20. PubMed ID: 2901023
[TBL] [Abstract][Full Text] [Related]
9. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.
Pert A; Rosenblatt JE; Sivit C; Pert CB; Bunney WE
Science; 1978 Jul; 201(4351):171-3. PubMed ID: 566468
[TBL] [Abstract][Full Text] [Related]
11. Effect of estradiol and haloperidol on hypophysectomized rat brain dopamine receptors.
Di Paolo T; Daigle M; Labrie F
Psychoneuroendocrinology; 1984; 9(4):399-404. PubMed ID: 6514934
[TBL] [Abstract][Full Text] [Related]
12. Chronic ganglioside treatment counteracts the biochemical signs of dopamine receptor supersensitivity induced by chronic haloperidol treatment.
Agnati LF; Fuxe K; Benfenati F; Battistini N; Zini I; Toffano G
Neurosci Lett; 1983 Oct; 40(3):293-7. PubMed ID: 6646502
[TBL] [Abstract][Full Text] [Related]
13. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
Bhargava HN
Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
15. Hypophysectomy reduces the haloperidol-induced changes in striatal dopamine receptor density.
Hruska RE; Pitman KT
Eur J Pharmacol; 1982 Nov; 85(2):201-5. PubMed ID: 7151867
[TBL] [Abstract][Full Text] [Related]
16. Repeated administration of HA-966 and haloperidol to rats: similar tolerance to striatal dopamine accumulation after HA-966 challenge, but dissimilar effects on striatal [3H]spiperone binding.
Van der Krogt JA; Van Valkenburg CF; Belfroid RD; Heerkens CB
Eur J Pharmacol; 1988 Dec; 158(1-2):29-35. PubMed ID: 3220118
[TBL] [Abstract][Full Text] [Related]
17. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
Bennett JP; Wooten GF
Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
Chiu S; Paulose CS; Mishra RK
Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
[TBL] [Abstract][Full Text] [Related]
19. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
Gulati A; Srimal RC; Dhawan BN
Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
[TBL] [Abstract][Full Text] [Related]
20. MIF-1 attenuates spiroperidol alteration of striatal dopamine D2 receptor ontogeny.
Saleh MI; Kostrzewa RM
Peptides; 1989; 10(1):35-9. PubMed ID: 2568624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
